GO
Loading...

Vivus Inc

More

  • Ahead of the Bell: Orexigen shares rise Friday, 27 Mar 2015 | 8:25 AM ET

    NEW YORK— The approval of a weight-loss drug by European regulators sent shares of Orexigen Therapeutics soaring 12 percent before the opening bell Friday. The drug competes with Belviq, made by Arena Pharmaceuticals Inc., and Qsymia, made by Vivus Inc.. Shares of Orexigen Therapeutics Inc., based in San Diego, rose 90 cents to $8.15 in premarket trading.

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder, as the company struggles with poor sales of its only drug on the market. Ariad's blood cancer drug, Iclusig, has failed to live up to sales expectations after the U.S. Food...

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc on Friday, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder. The hedge fund, Ariad's largest shareholder with a 6.87 percent stake, according to Thomson Reuters data, has been negotiating Berger's exit with some of...

  • Jan 7- Zafgen Inc said a mid-stage study showed its experimental drug reduced weight in patients obese due to damage to a part of the brain. Vivus Inc's Qsymia, Arena Pharmaceuticals Inc's Belviq and Orexigen Therapeutics Inc's Contrave appear to work by signaling the brain, but their exact mechanism of action is unknown. The U.S. Food and Drug Administration...

  • FDA approves Novo Nordisk's injection for obesity Tuesday, 23 Dec 2014 | 5:14 PM ET

    Dec 23- The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally. A study showed that half the patients given Saxenda lost at least 5...

  • Dec 19- European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade. The drug, sold as Contrave by partner Takeda Pharmaceutical Co in the United States, will be marketed as Mysimba in Europe. The third obesity...

  • Vivus shares rally on erectile dysfunction drug nod Thursday, 18 Sep 2014 | 8:14 AM ET

    An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.

  • Early movers: AAPL, MSFT, TGT, V, A, AMZN & more Thursday, 18 Sep 2014 | 7:57 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Here's a new way to lose weight Thursday, 11 Sep 2014 | 8:08 AM ET

    U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.

  • You’ve got obesity all wrong: Zafgen CEO Tuesday, 19 Aug 2014 | 10:45 AM ET

    Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.

  • Lightning Round: Akamai, GE & more Tuesday, 15 Jul 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Orexigen shares hit by FDA delay in obesity drug Wednesday, 11 Jun 2014 | 10:07 AM ET

    Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • Obesity game-changer? Why this time it's different Monday, 9 Jun 2014 | 12:45 PM ET

    An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.

  • Lightning Round: Starbucks, TriQuint & more Thursday, 29 May 2014 | 6:47 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Midday movers: Allergan, Apple, Brown Shoe Co. & More Wednesday, 28 May 2014 | 12:18 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Wednesday's midday movers:

  • Early movers: AAPL, CBS, OMC, PUB & more Friday, 9 May 2014 | 7:54 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Midday movers: Google, Barnes & Noble, Netflix & more Thursday, 3 Apr 2014 | 12:26 PM ET

    Take a look at some of Thursday's midday movers:

  • New ED drug takes over March Madness Thursday, 27 Mar 2014 | 3:45 PM ET

    The first drug to treat erectile dysfunction in almost a decade launched a huge marketing campaign Wednesday by taking over the CBS Sports website.

  • Docs push statins, gastric surgery for heart cures Tuesday, 12 Nov 2013 | 6:14 PM ET

    Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.